15.30

1.29% -0.20

Biodesix Inc (BDSX)

Overview News Price History Option Chain Financials Discussions Forecast

Biodesix Inc stock is traded at $15.30, with a volume of 133.61K. It is down -1.29% in the last 24 hours and up +48.54% over the past month. Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Previous Close:

$15.50

Open:

$15.62

24h Volume:

133.61K

Relative Volume:

0.10

Market Cap:

$121.72M

Revenue:

$49.09M

Net Income/Loss:

$-52.15M

P/E Ratio:

-23.54

EPS:

-0.65

Net Cash Flow:

$-45.93M

1W Performance:

+18.33%

1M Performance:

+48.54%

6M Performance:

+72.57%

1Y Performance:

+6.25%

1-Day Range:

$14.61

$15.87

1-Week Range:

$12.36

$17.40

52-Week Range:

$3.436

$19.13

Biodesix Inc Stock (BDSX) Company Profile

Name

Biodesix Inc

Sector

Healthcare (1106)

Industry

Diagnostics & Research (52)

Phone

303-417-0500

Address

919 WEST DILLON ROAD, LOUISVILLE

Employee

273

Twitter

Next Earnings Date

2025-10-31

Latest SEC Filings

BDSX's Discussions on Twitter

Compare BDSX vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDSX Biodesix Inc	15.30	123.31M	49.09M	-52.15M	-45.93M	-0.65
TMO Thermo Fisher Scientific Inc	512.69	190.90B	44.56B	6.73B	6.29B	17.74
DHR Danaher Corp	204.73	144.26B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	648.70	50.60B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	120.54	33.67B	6.95B	1.30B	1.15B	4.5696
WAT Waters Corp	319.04	30.62B	3.17B	642.63M	516.49M	10.77

Biodesix Inc Stock (BDSX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-14-25	Downgrade	William Blair	Outperform → Mkt Perform
Sep-16-24	Initiated	Scotiabank	Sector Outperform
Jul-26-24	Initiated	Craig Hallum	Buy
May-13-24	Initiated	TD Cowen	Buy
May-03-24	Initiated	Lake Street	Buy
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-23-20	Initiated	BTIG Research	Buy
Nov-23-20	Initiated	Canaccord Genuity	Buy
Nov-23-20	Initiated	Morgan Stanley	Overweight
Nov-23-20	Initiated	William Blair	Outperform

View All

Biodesix Inc Stock (BDSX) Latest News

Mar 03, 2026

Wall Street experts predict that Biodesix (BDSX) may climb by 111.62%: Consider this information before making an investment decision - Bitget

Mar 03, 2026

Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet - Finviz

Mar 03, 2026

Are healthcare stocks underperforming Biodesix (BDSX) so far this year? - Bitget

Mar 02, 2026

Canaccord reiterates Biodesix stock rating on strong Q4 results - Investing.com

Mar 02, 2026

Canaccord reiterates Biodesix stock rating on strong Q4 results By Investing.com - Investing.com UK

Mar 02, 2026

Mar 01, 2026

Biodesix (BDSX) Q4 2025 Earnings Call Transcript - AOL.com

Mar 01, 2026

Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX - MarketBeat

Mar 01, 2026

Feb 28, 2026

Q4 2025 Biodesix Inc Earnings Call Transcript - GuruFocus

Feb 28, 2026

William Blair Upgrades Biodesix (BDSX) - Nasdaq

Feb 28, 2026

Feb 27, 2026

William Blair Upgrades BDSX (Biodesix, Inc.) to Outperform Feb 2026 - Meyka

Feb 27, 2026

Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results, Beats Estimates By $0.56 EPS - MarketBeat

Feb 27, 2026

William Blair Upgrades Biodesix (BDSX) to 'Outperform' | BDSX St - GuruFocus

Feb 27, 2026

Biodesix expects 2026 sales to crack $100M - BizWest

Feb 27, 2026